Antithrombotic-Associated Bleeding

In this episode, Sam Ashoo, MD, Dr. Christopher Baugh, MD, MBA, and Dr. Xin Qi, MD, discuss the October 2026 Emergency Medicine Practice article, Antithrombotic-Associated Bleeding: Management in the Emergency Department.

1:18 — Guest introductions

1:58 — Why the authors chose this topic

3:11 — Epidemiology

4:27 — Why DOACs over warfarin

5:15 — Bleeding trends

6:55 — Overlapping antithrombotic regimens

8:09 — Reversibility of agents

9:38 — Bedside priorities

11:31 — Bleeding patterns by drug class & three groups

13:50 — Antithrombotics & traumatic bleeding risk

14:26 — Pre-hospital considerations

16:09 — Indications for antithrombotic use & risk of reversing

17:54 — Gray-area decisions

19:02 — Initial resuscitation

20:08 — Blood product ratios

21:24 — PATCH trial

22:04 — TXA evidence

23:36 — GI bleed adjuncts

24:31 — Critical site bleeds

27:20 — Endoscopy timing

30:00 — Reversal agents

32:50 — Idarucizumab for dabigatran

33:54 — Antiplatelet reversal

36:15 — Warfarin reversal

38:36 — Protamine for heparin/LMWH

39:37 — Fibrinolytic reversal

40:14 — Pre-procedural antithrombotic management

42:39 — Emerging labs

43:50 — Wrap-up & closing promo

Subscribers, take the CME test here.

Emergency Medicine Residents, get your free subscription by writing resident@ebmedicine.net